Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned or has not responded to treatment. Monoclonal antibodies, such as ipilimumab and rituximab, may interfere with the ability of cancer cells to grow and spread.
Critère d'inclusion
- CD20 Positive,Recurrent B-Cell Non-Hodgkin Lymphoma,Refractory B-Cell Non-Hodgkin Lymphoma